Navigation Links
An ideal therapy for peptic ulcer disease
Date:11/11/2008

Since the discovery of the etiological role of Helicobacter pylori (H pylori) in peptic ulcer disease, its eradication became the main objective of therapy, and several treatment regimens were developed. Currently, triple therapy with omeprazole, amoxicillin, and clarithromycin remains the best therapeutic option. Despite its efficacy, 10% to 20% of the patients present with treatment failure, demanding alternative therapeutic regimes with variable success rates. The development of effective salvage treatments is of paramount importance in this situation.

The research team led by Jaime Natan Eisig, from Brazil addresses this question and this will be be published on October 28; 2008 in the World Journal of Gastroenterology.

The therapeutic regimen consisted of 20 mg omeprazole, 240 mg colloidal bismuth subcitrate, 1000 mg amoxicillin, and 200 mg furazolidone, taken twice a day for seven days. Patients were considered as eradicated when samples taken from the gastric antrum and corpus twelve weeks the end of treatment were negative for H pylori (rapid urease test and histology). Safety was determined by the adverse effects.

In this study, fifty one patients were enrolled. The eradication rate was 68.8% (31/45). Adverse effects were reported by 31.4% of the patients, and these were usually considered to be slight or moderate in the majority of the cases. Three patients had to withdraw from the treatment due to the presence of severe adverse effect. Their result indicated that the association of bismuth, furazolidone, amoxicillin and a proton-pump inhibitor is a valuable alternative for peptic ulcer patients.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Jenny Craig Announces Finalists for the 2008 Ideal Size Contest
2. Through-Wave Ultrasound: Effective, Economical and Ideal for Breast Imaging, Biopsy
3. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
4. Sale of Enzymatic Therapy, Inc. to Natures Way Holding Company Finalized
5. Ellex Announces Six-Month Results on Retina Regeneration Therapy
6. ESF workshop makes major advance in cancer radiotherapy
7. 5th Annual Global Conference on Stem Cell Therapy to be held Jan. 13-16, 2009 in NYC
8. New Study Demonstrates Cost Effectiveness of NeuroStar TMS Therapy(R) in the Treatment of Depression
9. Hormone therapy helps short children grow up
10. Therapy may block expansion of breast cancer cells
11. TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Linda, Ca (PRWEB) , ... April 28, 2017 ... ... with cardiac or hERG liability could substantially improve drug safety and minimize the ... be provided for validating ion channel inhibition using cell lines and for cardiac ...
(Date:4/28/2017)... FL (PRWEB) , ... April 28, 2017 , ... ... Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub ... is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for ...
(Date:4/28/2017)... ... , ... NuevaCare, a leading home care agency based in San Mateo, California, ... proud to announce information upgrades to its blog in the form of WordPress tags. ... such as home care (generally) as well as senior care and home care agency ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The ... retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology: